Trial reportGut and liver2017
Efficacy of a Multiplex Paclitaxel Emission Stent Using a Pluronic
Trial report in Gut and liver, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 25 citations in OpenAlex.
- Advances in functional coatings on biliary stents.Regenerative biomaterials · 2024Review
- A Bayesian Network Meta-Analysis Comparing Biliary Stent Types' Outcome and Complications in Unresectable Malignant Biliary Obstructions.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Futuristic Developments and Applications in Endoluminal Stenting.Gastroenterology research and practice · 2022Review
- Endoscopic Palliation for Biliary and Pancreatic Malignancies: Recent Advances.Clinical endoscopy · 2019Article
- Safety Evaluation of Paclitaxel-Eluting Biliary Metal Stent with Sodium Caprate in Porcine Biliary Tract.Gut and liver · 2019Article
- Piperlongumine-Eluting Gastrointestinal Stent Using Reactive Oxygen Species-Sensitive Nanofiber Mats for Inhibition of Cholangiocarcinoma Cells.Nanoscale research letters · 2019Article
- Early Diagnosis And Management Of Malignant Distal Biliary Obstruction: A Review On Current Recommendations And Guidelines.Clinical and experimental gastroenterology · 2019Review
- Which Is Crucial, Strengthen the Foundation or Building the Dream House?Gut and liver · 2017Article
- Advances in the endoscopic management of malignant biliary obstruction.Annals of gastroenterologyReview
Corrections and comments
- Commented on by
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsA drug-eluting stent for unresectable malignant biliary obstruction was developed to increase stent patency by preventing tumor ingrowth. The safety and efficacy of a new generation of metallic stents covered with a paclitaxel-incorporated membrane using a Pluronic
methodsThis study was initially designed as a prospective randomized trial but was closed early because of a high incidence of early occlusion. Therefore, the data were analyzed using the intent-to-treat method. A total of 72 patients with unresectable distal malignant biliary obstructions were prospectively enrolled.
resultsThe two groups did not differ significantly in basic characteristics and mean follow-up period (MSCPM-II 194 days vs CMS 277 days, p=0.063). Stent occlusion occurred in 14 patients (35%) who received MSCPM-II and in seven patients (21.9%) who received CMSs. Stent patency and survival time did not significantly differ between the two groups (p=0.355 and p=0.570). The complications were mild and resolved by conservative management in both groups.
conclusionsThere were no significant differences in stent patency or patient survival in MSCPM-II and CMS patients with malignant biliary obstructions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.